Nantahala Capital Management LLC Has $20.88 Million Stock Position in Savara Inc (NASDAQ:SVRA)

Nantahala Capital Management LLC raised its position in Savara Inc (NASDAQ:SVRA) by 198.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,180,951 shares of the company’s stock after acquiring an additional 3,443,541 shares during the quarter. Savara makes up about 1.2% of Nantahala Capital Management LLC’s investment portfolio, making the stock its 9th largest holding. Nantahala Capital Management LLC owned 3.75% of Savara worth $20,879,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. ProShare Advisors LLC lifted its holdings in Savara by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after purchasing an additional 2,114 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Savara by 15.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after purchasing an additional 4,625 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Savara by 14.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock valued at $166,000 after purchasing an additional 5,335 shares during the period. Principal Financial Group Inc. grew its position in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co bought a new position in shares of Savara during the first quarter worth approximately $35,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on SVRA. Guggenheim increased their target price on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Savara in a research note on Wednesday, August 14th. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Monday, September 9th. Finally, Oppenheimer lifted their price objective on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, June 26th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Savara currently has an average rating of “Buy” and an average price target of $11.17.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $4.24 on Tuesday. Savara Inc has a one year low of $3.12 and a one year high of $5.70. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. The company has a market cap of $585.92 million, a price-to-earnings ratio of -11.46 and a beta of 0.97. The firm has a 50 day simple moving average of $4.33 and a 200 day simple moving average of $4.46.

Savara (NASDAQ:SVRA) last issued its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Research analysts predict that Savara Inc will post -0.44 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.